Innovative solution provides cell-based tools for translational research and development

May 07, 2019 08:00 AM Eastern Daylight Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces a unified portfolio of products for immunotherapy researchers. The innovative solution will showcase at Immunology 2019, the 103rd Annual Meeting of the American Association of Immunologists (AAI), taking place in San Diego, CA on May 9-13, 2019.

“Immunotherapy is changing the landscape of cancer treatment, but most of the available tools are adapted and not purpose-built for this cell-centric workflow,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies. “This is why we have placed so much emphasis on assembling and harmonizing innovative cell-based solutions. We want to enable researchers and developers to overcome the challenges and capture the opportunities of this rapidly growing field.”“To find the answers, flow cytometry approaches, kinetic measures of live-cell metabolism, and quantifying the ability of T cells to kill targets over time, are all aspects that can be investigated now with the tools that Agilent provides,” said Carl June, MD, professor in immunotherapy at the Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center. “Any cell-based assay that improves the probability that you’re going to have an effective cell product will be something that everyone wants.”Agilent’s new offering includes four purpose-built components that naturally complement:

• Agilent SureGuide Chemically Synthesized sgRNAs: Deliver the best guides to enable the full potential of CRISPR for cellular engineering and immunotherapy.
• NovoCyte Quanteon Flow Cytometer: Quickly and accurately immunophenotype with up to 25 channels of fluorescence using the most sensitive silicon photomultiplier detector technology on the market. Experience the new standard in flow cytometry.
• xCELLigence RTCA eSight: Capture dynamic cell behavior and follow the biology that can be missed by labor-intensive endpoint assays to quantify, in real-time critical events like cancer cell killing.
• Agilent Seahorse XF Analyzers: Discover and tune immune cell metabolism to mount a sustained and robust anti-tumor response. XF analyzers are the market leading choice for this type of work.

An Agilent workshop titled Breakthroughs in immunotherapy: Tune the drivers of immune cell potency, fate and persistence, presented by David Ferrick, will be held on Sunday, May 12, 10:00 - 10:45 a.m. in Room 2 of the San Diego Convention Center, Exhibit Halls F & G. To learn more, visit the Agilent booth #1315 and the ACEA (a part of Agilent) booth #1030 at Immunology 2019, or go to www.agilent.com/en/solutions/cell-metabolism/immune-cell-therapy.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Naomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com

Source: https://www.businesswire.com/news/home/20190507005389/en/Agilent-Announces-Unique-Portfolio-Advance-Immunotherapy